Skip to Content

View Additional Section Content

CP3R and AJH’s Performance for Non-Small Cell Lung Cancer

SURGERY IS NOT FIRST COURSE OF TREATMENT FOR NON-SMALL CELL LUNG CANCER THAT HAS NOT SPREAD TO DISTANT ORGANS OR AREAS

Surgery is not First Course of Treatment for Non-Small Cell Lung Cancer That Has Not Spread to Distant Organs or Areas

This quality measure examines whether surgery was used within the first course of treatment for Non-Small Cell Lung Cancer that has not spread to other organs. Abington – Jefferson Health’s compliance rate of 85.7% is below the CoC standard rate of 90.5%.


CHEMOTHERAPY IN LYMPH NODE POSITIVE NON-SMALL CELL LUNG CANCER

Chemotherapy in Lymph Node Positive Non-Small Cell Lung Cancer

Chemotherapy administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node positive Non-Small Cell Lung Cancer. Abington – Jefferson Health’s compliance is 66.7% compared to the CoC average of 88.3%.


LYMPH NODES IN NON-SMALL CELL LUNG CANCER

Lymph Nodes in Non-Small Cell Lung Cancer

At least 10 regional lymph nodes are removed and pathologically examined for Non-Small Cell Lung Cancer. Abington – Jefferson Health’s compliance with this standard is 40%, favorable compared to the CoC compliance rate of 39%.